Thu, 06 May 2021 11:22:16 GMT
Regeneron Q1 profit soars
On Thursday, Regeneron Pharmaceuticals reported its Q1 profit surged as much as 78%, driven by strong demand recovery of its Eylea eye drug and ongoing strength in the Dupixent eczema drug's sales.